Clinical Trials Logo

Filter by:
NCT ID: NCT05055258 Recruiting - Clinical trials for Angioedema, Hereditary, Types I and II

Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

KVD824-201
Start date: September 17, 2021
Phase: Phase 2
Study type: Interventional

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

NCT ID: NCT05054530 Not yet recruiting - Clinical trials for Overweight and Obesity

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Start date: October 14, 2021
Phase: Phase 1
Study type: Interventional

This will be a single centre, Phase 1, placebo-controlled, randomized, doubleblind, sequential SAD study to assess the safety, tolerability, and PK of GMA106 in healthy subjects.

NCT ID: NCT05053854 Recruiting - Clinical trials for Neuroendocrine Tumors

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

PARLuNET
Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic neuroendocrine tumour (NET).

NCT ID: NCT05053165 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Phase 1 Study to Assess the Safety and Tolerability of Multiple Ascending Doses of LB-P6 and LB-P8 in Healthy Participants

Start date: October 12, 2021
Phase: Phase 1
Study type: Interventional

The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.

NCT ID: NCT05050097 Not yet recruiting - Multiple Myeloma Clinical Trials

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Start date: September 20, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

NCT ID: NCT05049512 Not yet recruiting - Allergy, Nut Clinical Trials

Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy

LMNOP
Start date: October 2021
Phase: N/A
Study type: Interventional

The LMNOP trial will be a 2-armed, open-label, randomised controlled trial (RCT), 2:1. Over a period of 18 months, children in the Multi-Nut Oral Immunotherapy Treatment (OIT) Group (experimental arm) will undergo low dose OIT to two nuts they are allergic to. At this time, children in the Standard Care Group (control arm) will be instructed to strictly avoid consuming two nuts they are allergic to. Avoiding consuming nut allergens is the standard care advice for children with peanut/tree nut allergies in Australia. The trial will assess the difference in the proportion of participants undergoing Multi-Nut OIT who can achieve sustained unresponsiveness (SU) compared to the proportion of participants avoiding nuts who develop natural tolerance (NT), i.e. grow out of their allergy. SU is when a participant can pass an oral food challenge (OFC) after having paused OIT treatment for several weeks. Participants will be between the ages of 18 and 36 months at the time of screening. The first 12 participants enrolled will be part of the pilot phase, with a total of n = 45 for the main trial. It is hypothesised that there will be a higher proportion of participants in the Multi-Nut OIT Group versus the Standard Care Group who pass the OFC following the 18-month treatment phase. That is, a higher proportion of participants in the Multi-Nut OIT Group will achieve SU compared to participants in the Standard Care Group achieving NT.

NCT ID: NCT05048056 Not yet recruiting - Atopic Dermatitis Clinical Trials

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Start date: September 10, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

NCT ID: NCT05047263 Not yet recruiting - Clinical trials for Non-diabetic Chronic Kidney Disease

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

FIND-CKD
Start date: September 21, 2021
Phase: Phase 3
Study type: Interventional

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old. The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months. During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.

NCT ID: NCT05046665 Recruiting - Clinical trials for Urothelial Carcinoma

A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study)

ZiPUP
Start date: May 14, 2021
Phase: Phase 1
Study type: Interventional

The aim of this study is to determine if it is practical to use 89Zr-TLX250 PET/CT in the staging and detection of localized and metastatic urothelial carcinoma or bladder cancer. The primary objective is to evaluate the feasibility of using 89Zr-TLX250 PET/CTas a new diagnostic and staging modality to detect urothelial carcinoma or bladder cancer.

NCT ID: NCT05046522 Recruiting - Migraine Clinical Trials

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy participants aged 18 years and older.